Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles

Journal of Controlled Release

Volumn 140, Issue 2, 2009, Pages 95-99

  Fu, Ju Yen ^a   Blatchford, David R ^a   Tetley, Laurence ^b   Dufès, Christine ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cancer therapy; Delivery system; Tocotrienol; Transferrin; Tumor targeting

Indexed keywords

CANCER THERAPY; DELIVERY SYSTEM; TOCOTRIENOL; TRANSFERRIN; TUMOR TARGETING;

ANIMALS; BEARINGS (STRUCTURAL); BIOLOGICAL MATERIALS; CELL CULTURE; ENCAPSULATION; ENZYME INHIBITION; ONCOLOGY; REGRESSION ANALYSIS; VITAMINS;

TUMORS;

ALPHA TOCOTRIENOL; TRANSFERRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; DRUG UPTAKE; ENCAPSULATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; SURVIVAL; SYSTEMIC THERAPY; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL SURVIVAL; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; PARTICLE SIZE; RECEPTORS, TRANSFERRIN; SOLVENTS; TIME FACTORS; TOCOTRIENOLS; TRANSFERRIN; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350617697     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.08.017     Document Type: Article

References (17)

1. Constantinou C., Papas A., and Constantinou A.I. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int. J. Cancer 123 (2008) 739-752
2. Nesaretnam K. Multitargeted therapy of cancer by tocotrienol. Cancer Lett. 269 (2008) 88-395
3. Wada S., Satomi Y., Murakoshi M., Noguchi N., Yoshikawa T., and Nishino H. Tumor suppressive effects of tocotrienol in vivo and in vitro. Cancer Lett. 229 (2005) 181-191
4. Miyazawa T., Shibata A., Sookwong P., Kawakami Y., Eitsuka T., Asai A., Oikawa S., and Nakagawa K. Antiangiogenic and anticancer potential of unsaturated vitamin E (tocotrienol). J. Nutr. Biochem. 20 (2009) 79-86
5. Daniels T.R., Delgado T., Helguera G., and Penichet M.L. The transferrin receptor part II : targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 121 (2006) 159-176
6. Calzolari A., Oliviero I., Deaglio S., Mariani G., Biffoni M., Sposi N.M., Malavasi F., Peschle C., and Testa U. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol. Diseases 39 (2007) 82-91
7. Maeda H. The tumor blood vessel as an ideal target for macromolecular anticancer agents. J. Control. Release 19 (1992) 315-324
8. Qian Z.M., Li H., Sun H., and Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol. Rev. 54 (2002) 561-587
9. Dufès C., Schätzlein A.G., Tetley L., Gray A.I., Watson D.G., Olivier J.C., Couet W., and Uchegbu I.F. Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting. Pharm. Res. 17 (2000) 1250-1258
10. Dufès C., Muller J.M., Couet W., Olivier J.C., Uchegbu I.F., and Schätzlein A.G. Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles. Pharm. Res. 21 (2004) 101-107
11. Plumb J.A., Milroy R., and Kaye S.B. Effects of the pH dependence of 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 49 (1989) 4435-4440
12. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., Verweij J., Van Glabbeke M., Van Oosterom A.T., Christian M.C., and Gwyther S.G. New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
13. Yuan F., Dellian M., Fukumura D., Leunig M., Berk D.A., Torchilin V.P., and Jain R.K. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55 (1995) 3752-3756
14. Ishida O., Maruyama K., Sasaki K., and Iwatsuru M. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int. J. Pharm. 193 (1999) 49-56
15. Kong G., Braun R.D., and Dewhirst M.W. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res. 60 (2000) 4440-4445
16. Mahato R.I., Smith L.C., and Rolland A. Pharmaceutical perspectives of nonviral gene therapy. Adv. Genet. 41 (1999) 95-156
17. McIntyre B.S., Briski K.P., Gapor A., and Sylvester P.W. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc. Soc. Exp. Biol. Med. 224 (2000) 292-301